Healthcare / Medical DevicesTokyo
$290.00
+20.00 (+7.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-735.0M · quality 61.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$61.2B
P/E
397.3x
↑EV/EBITDA
3431.4x
↑ROE
-1.5%
↓Gross Margin
54.1%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+26.8%
FCF CAGR
—
FCF margin
-16.8%
FCF / Net income
1.27x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.38B · net income $-577.0M · FCF $-735.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.38B | $4.38B | $4.35B | $3.29B | $2.15B |
| Net Income | $-577.0M | $-577.0M | $-1.48B | $-298.0M | $-498.0M |
| EBITDA | $16.0M | $16.0M | $18.0M | $873.0M | $97.0M |
| EPS | -2.73 | -2.73 | -6.99 | -1.39 | — |
| Gross Margin | 54.1% | 54.1% | 55.0% | 54.5% | 68.0% |
| Operating Margin | -21.1% | -21.1% | -46.3% | -34.8% | -40.9% |
| Net Margin | -13.2% | -13.2% | -33.9% | -9.1% | -23.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 |
| Current Ratio | 14.31 | 14.31 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-735.0M | $-735.0M | $-1.07B | $-652.0M | $-2.34B |
| Returns | |||||
| ROE | -1.5% | -1.5% | -3.6% | -0.7% | -1.1% |
| Valuation | |||||
| P/E | 397.26 | 397.26 | — | — | — |
| EV/EBITDA | 3431.44 | 3431.44 | 2083.20 | 60.69 | 754.71 |
| P/B | 1.55 | 1.55 | 1.03 | 1.43 | 1.80 |
| Growth & Yield | |||||
| Revenue Growth | 0.7% | 0.7% | 32.4% | 53.0% | — |
| EPS Growth | 60.9% | 60.9% | -402.9% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+70.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-6.99 → -2.73
Residual
+70.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.